Carisoprodol — Discount Pricing

Other medications in Pain & Inflammation

• Chlorzoxazone
• Codeine
• Dantrolene
• Diclofenac Gel
• Diclofenac Patch
• Diflunisal
• Dihydroergotamine
• Eletriptan

About Carisoprodol

Carisoprodol is a prescription muscle relaxant often used for short-term relief of acute musculoskeletal pain. If you're managing muscle spasms and discomfort, understanding your medication and its potential costs is crucial. TheDrugClub helps members navigate prescription pricing, potentially offering significant savings on medications like carisoprodol.

Carisoprodol is a medication prescribed to alleviate the discomfort associated with acute, painful musculoskeletal conditions, such as muscle spasms, strains, or injuries. It's typically used as part of a comprehensive treatment plan that includes rest, physical therapy, and other measures. It's important to note that carisoprodol is generally intended for short-term use, usually no more than two to three weeks, due to its potential for dependence and side effects.

How Carisoprodol Works

Carisop

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Carisoprodol is approved for (FDA label)

Carisoprodol is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use Carisoprodol should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [ see Dosage and Administration (2) ]. Carisoprodol is a muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. (1) Limitations of Use Should only be used for acute treatment periods up to two or three weeks ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Carisoprodol (FDA label)

350 mg Tablets: round, convex, white tablets, inscribed with 111 on one side and “O” on the other side. Tablets: 350 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: b83f7fd1-11e3-4e94-ae53-4637e892b372. SPL document ID: 57c1bd8a-316c-6032-e063-6294a90aa784. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Carisoprodol (FDA label)

Most common adverse reactions (incidence > 2%) are drowsiness, dizziness, and headache (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Oxford Pharmaceuticals LLC at 1-844 508 1455 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: b83f7fd1-11e3-4e94-ae53-4637e892b372. SPL document ID: 57c1bd8a-316c-6032-e063-6294a90aa784. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Carisoprodol (FDA label)

Carisoprodol is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. Acute intermittent porphyria (4) Hypersensitivity reactions to a carbamate such as meprobamate (4)

Source: FDA prescribing information (DailyMed). Set ID: b83f7fd1-11e3-4e94-ae53-4637e892b372. SPL document ID: 57c1bd8a-316c-6032-e063-6294a90aa784. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Carisoprodol (FDA label)

Due to sedative properties, may impair ability to perform hazardous tasks such as driving or operating machinery (5.1) Additive sedative effects when used with other CNS depressants including alcohol (5.1) Cases of abuse, dependence and withdrawal ( 5.2 , 9.2 , 9.3 ) Seizures (5.3) 5.1 Sedation Carisoprodol has sedative properties (in the low back pain trials, 13% to 17% of patients who received carisoprodol experienced sedation compared to 6% of patients who received placebo) [ see ADVERSE REACTIONS (6.1) ] and may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or operating machinery. There have been post-marketing reports of motor vehicle accidents associated with the use of carisoprodol.

Source: FDA prescribing information (DailyMed). Set ID: b83f7fd1-11e3-4e94-ae53-4637e892b372. SPL document ID: 57c1bd8a-316c-6032-e063-6294a90aa784. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Carisoprodol (FDA label)

CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) - additive sedative effects ( 5.1 , 7.1 ) 7.1 CNS Depressants The sedative effects of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive. Therefore, caution should be exercised with patients who take more than one of these CNS depressants simultaneously. Concomitant use of carisoprodol and meprobamate, a metabolite of carisoprodol, is not recommended [ see Warnings and Precautions (5.1) ]. 7.2 CYP2C19 Inhibitors and Inducers Carisoprodol is metabolized in the liver by CYP2C19 to form meprobamate [ see Clinical Pharmacology (12.3) ]. Co-administration of CYP2C19 inhibitors, such as omeprazole or fluvoxamine, with carisoprodol could result in increased exposure of carisoprodol and decreased exposure of meprobamate. Co-administration of CYP2C19 inducers, such as rifampin or St. John’s Wort, with carisoprodol could result in decreased exposure of carisoprodol and increased exposure of meprobamate.

Source: FDA prescribing information (DailyMed). Set ID: b83f7fd1-11e3-4e94-ae53-4637e892b372. SPL document ID: 57c1bd8a-316c-6032-e063-6294a90aa784. Label effective date: July 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.